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Background: Impressive achievements have been made towards achieving universal coverage of antiretroviral
therapy (ART) in sub-Saharan Africa. However, the effects of rapid ART scale-up on delays between HIV diagnosis
and treatment initiation have not been well described.
Methods: A retrospective cohort study covering eight years of ART initiators (2004–2011) was conducted at Queen
Elizabeth Central Hospital (QECH) in Blantyre, Malawi. The time between most recent positive HIV test and ART
initiation was calculated and temporal trends in delay to initiation were described. Factors associated with time to
initiation were investigated using multivariate regression analysis.
Results: From 2004–2011, there were 15,949 ART initiations at QECH (56% female; 8% children [0–10 years] and 5%
adolescents [10–20 years]). Male initiators were likely to have more advanced HIV infection at initiation than female
initiators (70% vs. 64% in WHO stage 3 or 4). Over the eight years studied, there were declines in treatment delay,
with 2011 having the shortest delay at 36.5 days. On multivariate analysis CD4 count <50 cells/μl (adjusted
geometric mean ratio [aGMR]: aGMR: 0.53, bias-corrected accelerated [BCA] 95% CI: 0.42-0.68) was associated with
shorter ART treatment delay. Women (aGMR: 1.12, BCA 95% CI: 1.03-1.22) and patients diagnosed with HIV at
another facility outside QECH (aGMR: 1.61, BCA 95% CI: 1.47-1.77) had significantly longer treatment delay.
Conclusions: Continued improvements in treatment delays provide evidence that universal access to ART can be
achieved using the public health approach adopted by Malawi However, the longer delays for women and patients
diagnosed at outlying sites emphasises the need for targeted interventions to support equitable access for these
groups.
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Since 2003, there have been tremendous global achieve-
ments in scaling up delivery of antiretroviral therapy
(ART) for people infected with HIV, with over 6.6 million
people now receiving treatment [1]. The most impressive
gains have been seen in sub-Saharan Africa. In 2009, 3.9
million people in the region were taking ART but by the* Correspondence: p.macpherson@liverpool.ac.uk
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reproduction in any medium, provided the orend of 2011, more than 5.1 million people had been initi-
ated onto ART, a 27% increase [2].
Malawi, one of the poorest countries in the world,
has pioneered the public health approach to ART
delivery [3,4]. The public health approach involves
decentralisation of ART delivery to primary health care
clinics, task-shifting from clinicians to nurses and
counsellors, and a reporting system based on collection
of facility-level aggregate statistics that allow clear
analysis of trends in HIV testing data, uptake of ART
and outcomes of ART initiators [5]. By mid-2011, more
than 400,000 HIV-infected Malawians had initiated
ART through the National Programme [6].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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have been impressive in their speed, impact upon popu-
lation mortality and on reducing HIV incidence [2],
there are increasing concerns about the effect that an
ever-expanding number of patients requiring life-long
clinical management will have on staff workload and
ART clinic sustainability. Moreover, a recent systematic
review has highlighted the high rate of attrition in the
pre-ART period [7], with long delays and failures to
complete eligibility assessments (CD4 counts and WHO
clinical staging assessments) major contributors to sub-
optimal retention before initiation [8]. Alternatively, as
ART guidelines are expanded to include individuals with
higher CD4 counts, treatment delays may be shortened.
This study examined changing patterns in length of
time between diagnosis of HIV infection and initiation
of antiretroviral therapy (“ART treatment delay”) at the
largest single public health facility providing ART in
Malawi over eight years. The objectives were to describe
temporal trends in ART treatment delay and investigate
factors associated with increased risk of delay since ART
became available free-of-charge at the clinic.Methods
Study design
A retrospective cohort study.Figure 1 Temporal trends in delay from HIV diagnosis to ART initiatio
2004–2011, and evolution of national treatment guidelines. TLC: totalStudy site and population
Queen Elizabeth Central Hospital (QECH) is the largest
public health facility in Malawi and is a referral centre
for patients in the Southern Region of the country. The
ART clinic at QECH was established as a fee-paying
clinic in 2000 and since 2004, ART has been provided
free-of-charge according to the National Ministry of
Health scale-up programme. The QECH ART clinic
profile and outcomes of patients initiating ART have
been described in detail previously [9].
Clinical and socio-demographic details of all ART ini-
tiators have been prospectively entered into the clinic’s
electronic data management system [10] since 2008.
Records of ART initiators before this date have been
retrospectively captured and validated.
From 2003 until 2006, Malawi National ART eligibility
criteria for adults (≥15 years) were presence of a WHO
stage 3 or 4 defining illness, or a CD4 count of <200 cells/
μl, or a total lymphocyte count (TLC) in an individual in
WHO stage 2 of <1200 cells/μl (Figure 1). The CD4 count
threshold was revised upwards to a cut-off of <250 cells/μl
in 2006 and to <350 cells/μl in September 2011.
For children less than 15 years old ART initiation
guidelines in Malawi have evolved in line with the publi-
cation of new evidence over the years. From, 2003 to
2006, children younger than 18 months old who were
eligible for ART if their CD4 percentage was < 25% orn at Queen Elizabeth Central Hospital, Blantyre, Malawi:
lymphocyte count.
Table 1 Baseline characteristics of ART initiators at Queen
Elizabeth Central Hospital between 2004 and 2011
Variable Female % Male % P-value
Total 8,988 6,961
Median age at initiation
(years); IQR
31 25-38 34 27-42 <0.001
Age group at initiation
0-5 years 475 5.3 537 7.8 <0.001
5-15 years 583 6.5 521 7.5
15-25 years 1,042 11.7 335 4.9
25-35 years 3,715 41.6 2,033 29.4
35-45 years 2,077 23.3 2,091 30.3
≥ 45 years 1,040 11.6 1,387 20.1
Site of HIV test
QECH 3,023 33.6 2,361 33.9 0.860
Outside QECH 4,140 46.1 3,176 45.6
Unknown 1,825 20.3 1,424 20.5
WHO stage at initiation
Stage 1 or 2 3,264 36.3 2,094 30.1 <0.001
Stage 3 or 4 5,724 63.7 4,867 69.9
CD4 count (cells/μl)*
≥ 350 167 3.8 103 3.1 <0.001
250 – 350 1,013 22.9 755 22.7
50 – 250 2,719 61.4 1,930 58.1
<50 528 11.9 533 16.1
Year of ART initiation
2004-2005 562 6.3 404 5.8 <0.001
2005-2006 1,208 13.4 801 11.5
2006-2007 1,250 13.9 887 12.7
2007-2008 1,253 13.9 1,010 14.5
2008-2009 1,249 13.9 964 13.9
2009-2010 1,134 12.6 1,024 14.7
2010-2011 1,154 12.8 1,002 14.4
2011-2012 1,178 13.1 866 12.4
Median time (days)
between last positive
HIV test and initiation of
ART; IQR
36 14-120 33 12-94 0.001
*CD4 count measured in 4,427 women and 3,321 men. Denominator for this
variable is number of men and women who had CD4 count measured.
Sloan et al. BMC Public Health 2013, 13:490 Page 3 of 7
http://www.biomedcentral.com/1471-2458/13/490they were in WHO paediatric stage 3 or 4. Children
aged older than 18 months if their CD4 percentage was
< 15%. As new evidence became available the guidelines
were updated and the thresholds for starting ART in
asymptomatic children lowered. In 2008 national guide-
lines were updated to recommend that all children aged
younger than 12 months with a confirmed or presumed
diagnosis of HIV were universally eligible for ART,
regardless of immune status. This was extended to all
children younger than 24 months in September 2011.
In this study, we extracted data from the ART clinic
database for the period from January 2004 to December
2011 when ART was available free-of-charge. Individuals
who initiated ART between 2004 and 2011 (regardless of
date of HIV diagnosis) were eligible for inclusion.
Defining ART treatment delay
Cohort entry was defined as the date of most recent
positive HIV test recorded in the ART clinic database.
Cohort exit was defined as the date of ART initiation.
Where either the date of last positive HIV test or the
date of ART initiation was missing from the database,
the patient was not included in the analysis.
Statistical methods
Statistical analysis was conducted using Stata/IC 11.2
(College Station, Texas, USA). Baseline characteristics of
ART initiators were stratified by sex and compared using
Pearson’s chi-square tests for categorical variables and
Student’s t test for continuous variables. Children were
defined as being between 0 and 10 years at ART ini-
tiation and adolescents between 10 and 20 years at
initiation.
Number of days between last positive HIV test and
initiation of ART showed a highly skewed distribution
and results were therefore transformed to loge before
analysis. Mean number of days to ART initiation was
compared between groups and by cohort year using
linear regression with back-transformation of regression
coefficients to obtain geometric mean ratios (GMRs). As
some results remained skewed after loge transformation,
analyses were bootstrapped with 10,000 repetitions to
estimate bias-corrected accelerated confidence intervals.
Variables considered as a priori confounders (age, sex,
CD4 count, year of initiation), and variables that were
significant at the p < 0.10 level on univariate analysis,
were included in the adjusted multivariate model.
Ethical considerations
The College of Medicine of Malawi Research Ethics
Committee granted ethical approval for this study. As
this was a retrospective study analysing routinely collected
data, individual consent was not sought. All patient identi-
fiers were removed prior to analysis.Results
Baseline characteristics
Between January 2004 and December 2011, there were
15,949 ART initiations at the QECH ART Clinic, with
more females (8,988, 56.4%) than males (6,961, 43.6%)
starting treatment. Characteristics of the ART initiators,
stratified by sex, are shown in Table 1. Male initiators
were older than female initiators (median: 34 years,
interquartile range [IQR]: 27–42 vs. 31 years, IQR: 25–38;
p < 0.001) and were more likely to have to have advanced
HIV infection at initiation: 4,876/6,961 (69.9%) of male
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(63.7%) of female initiators (p < 0.001); and a greater pro-
portion of male initiators (533/3,321, 16.1%) had a CD4
count of <50 cells/μl at initiation compared to female initi-
ators (528/4,427, 11.9%).
There were no differences in the site of the last posi-
tive HIV test, with a similar proportion of males (3,176/
6961, 45.6%) and females (4,140/8,988, 46.1%) testing at
sites outside of QECH (p = 0.860).
Child and adolescent ART initiators
Similar proportions of child (0–10 years) ART initiators
were male (884/1,694, 52.2%) and female (810/1,694,
47.8%). However, adolescent (10–20 years) initiators
were significantly less likely to be male than female
(342/856 [40.0%] vs. 514/856 [60.0%]). Adolescents had
the highest proportion of ART initiators who were in
WHO stage 3 or 4 (614/586, 71.7%) compared to children
(1,089/1,694, 64.3%) and adults older than 20 years (8,888/
13,399, 66.3%). Additionally, adolescents (58/380, 15.3%)
were most likely to initiate ART with a CD4 count of <50
cells/μl compared to children (33/666, 5.0%) and adults
(970/6,702, 14.5%).
Temporal trends in delay from last positive HIV test to
initiation of ART
In total, 9,511/15,949 (59.6%) ART initiators had
complete data for date of ART initiation and date of
most recent positive HIV test with the remaining 40.4%
of individuals having missing data for either date of ART
initiation, HTC or both. There were no differences be-
tween individuals with missing and non-missing out-
come data in terms of age group, sex and CD4 count
strata. However, individuals initiating ART at QECH
were less likely to have missing date of HIV diagnosis
than individuals initiating ART at another clinical site.
The overall median treatment delay in the group with
complete data for delay in ART initiation was 35 days
(IQR: 13–107).
Men (33 days, IQR: 12–94) had a shorter median ART
treatment delay compared to women (36 days, IQR: 14–
120; p = 0.001). There were slightly longer median time
to initiation for children (40 days, IQR: 14–114) and
adolescents (39 days, IQR: 13–127) compared to adults
(34 days, IQR: 13–105); p < 0.001.
In the years immediately following introduction of free
ART in the clinic, there was a trend towards increasing
ART treatment delay (Figure 1), with a peak in 2005
(geometric mean: 67.3 days, 95% CI: 58.9 – 76.8). How-
ever between 2005 and 2007, there was a rapid decline
in ART treatment delay to a lowest geometric mean of
43.3 days (95% CI: 39.7 – 47.3). Between 2007 and 2010,
there was a slow upwards trend in treatment delay, but
followed by a sharp decline in 2011, where the geometricmean number of days of ART treatment delay was 36.5
days (95% CI: 33.7-39.6).
Clinical and temporal associations with time from last
positive HIV test to initiation of ART
On univariate analysis (Table 2), female initiators experi-
enced longer treatment delays (geometric mean ratio
[GMR]: 1.13, bias corrected accelerated [BCA] 95% CI:
1.06-1.21) compared to male initiators. Younger children
in the 0–5 years age group had shorter treatment delays
(GMR: 0.87, BCA 95% CI: 0.75-0.99), compared to adults
in the 25–35 years age group, whereas older children and
adolescents in the 5–15 year age group were had a longer
delays (GMR: 1.16, BCA 95% CI: 0.99-1.37).
ART initiators whose last positive test for HIV was at
a clinical facility outside of QECH (any other HIV care
facility) were more likely to experience delay (GMR:
1.65, BCA 95% CI: 1.54-1.77). Whereas advanced WHO
clinical stage (stage 3 or 4) was not associated with delay
(GMR: 1.01, BCA 95% CI: 0.95-1.08), individuals with an
initiation CD4 count of <50 cells/μl (GMR: 0.50, BCA
95% CI: 0.40-0.63) and 50–200 cells/μl (GMR: 0.76,
BCA: 0.61-0.95) had significantly lower treatment delay
than individuals with a CD4 count of ≥ 350 cells/μl.
When examined by year, a trend of significantly declin-
ing ART treatment delay compared to the year with the
longest time from HIV-positive test to ART initiation
(2005) was seen (test for trend p < 0.001). The lowest risk
of delay was in 2011 (GMR: 0.54, BCA 95% CI: 0.47-0.63).
On multivariate adjusted analysis, women remained
more likely to experience a longer ART treatment delay
than men (adjusted GMR [aGMR]: 1.12, BCA 95% CI:
1.03-1.22), however there was no significant association
between age group at initiation and delay (p = 0.526).
Individuals whose last positive HIV test was outside of
QECH had a longer delay to ART initiation (aGMR:
1.61, BCA 95% CI: 1.47-1.77). Lower CD4 count
remained significantly associated with shorter delay to
initiation, with individuals in the <50 cells/μl group
(aGMR: 0.53, BCA 95% CI: 0.42-0.68) and the 50–200
cells/μl group (aGMR: 0.77, BCA 95% CI: 0.62-0.98)
compared to those in the ≥350 group. There remained a
non-significant trend towards shorter delay over the
years studies (test for trend: p = 0.089).
Discussion
The main finding from the study was the evidence of
sustained improvements in ART treatment delay from
most recent positive HIV test to initiation of ART over
eight years of rapid programmatic scale-up, a period
during which nearly 16,000 individuals initiated treat-
ment. The most recent year that was analysed (2011)
had the shortest mean treatment delay, suggesting that
the public health approach to ART delivery [3] that is
Table 2 Univariate and multivariate associations with
time from last positive HIV test and initiation of ART
Variable GMR± 95% CI* Adjusted
GMR±
95% CI* P
Sex
Men 1 1 0.007
Women 1.13 1.06-1.21 1.12 1.03-1.22
Age group
0-5 years 0.87 0.75-0.99 1.02 0.84-1.24 0.526
5-15 years 1.16 0.99-1.37 1.14 0.93-1.39
15-25 years 1.00 0.89-1.23 0.93 0.81-1.08
25-35 years 1 1
35-45 years 1.00 0.92-1.08 0.96 0.87-1.06
≥ 45 years 1.00 0.90-1.10 0.96 0.84-1.09
Site of HIV test
QECH 1 1
Facility other
than QECH
1.65 1.54-1.77 1.61 1.47-1.77 <0.001
Unknown 1.82 1.64-2.02 1.93 1.66-2.24
WHO stage at
registration
Stage 1 or 2 1
Stage 3 or 4 1.01 0.95-1.08
CD4 count
(cells/μl)
≥ 350 1 1 <0.001
250 – 350 0.87 0.70-1.11 0.96 0.75-1.20
50 – 250 0.76 0.61-0.95 0.77 0.62-0.98
<50 0.50 0.40-0.63 0.53 0.42-0.68
Year of ART
initiation
2004 0.92 0.75-1.14 0.79 0.52-1.21 0.004
2005 1 1
2006 0.72 0.60-0.87 0.75 0.48-1.16
2007 0.64 0.55-0.76 0.71 0.50-1.03
2008 0.68 0.59-0.80 0.72 0.51-1.02
2009 0.69 0.59-0.80 0.69 0.49-0.99
2010 0.75 0.64-0.88 0.85 0.60-1.21
2011 0.54 0.47-0.63 0.84 0.59-1.21
Number of ART
initiators per year
(continuous)
1.00 1.00-1.00
±Bootstrapped estimates of geometric mean ratios, adjusted for sex, age
group, site of HIV test, CD4 count strata and year of ART initiation.
*Bias corrected accelerated 95% confidence intervals.
GMR Geometric mean ratio, CI confidence interval, QECH Queen Elizabeth
Central Hospital.
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implemented at QECH, continues to meet its objective of
providing rapid access to ART despite extremely limited
resources.
In September 2011, new Malawian National ART guide-
lines were introduced promoting initiation of ART for HIV-infected individuals with a CD4 count of <350 cells/μl, or
in WHO stage 3 or 4, or who are pregnant or breastfeeding
[11]. Given the long experience of providing ART with no
appreciable increase in delay seen in this study, we antici-
pate that time to initiation will continue to shorten –
although with a greater number of potential patients
meeting eligibility criteria, current levels of resourcing will
need to be sustained or increased. This study found an
overall median treatment delay of 35 days, although this
varied cover time and was considerably shorter in more
recent years. This compares similarly with other national
programmes in the region: a recent systematic review
found that the majority of ART initiators started treat-
ment within one month [12], although two studies
reported higher median delays of 2.4 months [13] and 6.6
months [14].
A key success to the sustainability of the Malawian
national programme has been decentralisation of ART
services from tertiary facilities to primary health care
centres [15]. However, we found that patients who were
diagnosed with HIV at a site outside of QECH and sub-
sequently attended QECH for ART initiation were sig-
nificantly more likely to experience delay. This may have
been because, unlike patients who were diagnosed
within QECH, they would have had to make repeated
journeys to the hospital for ART eligibility assessments
and treatment education classes [16]. Further, patients
who were diagnosed at a primary care facility and opted
to initiate ART at QECH may have had more complex
clinical problems requiring specialist care that delayed
ART initiation. Alternatively, they may have been
reluctant to return to the primary health care centre
for treatment because of anticipated stigma or previous
bad experiences with providers [17]. Finally, individ-
uals diagnosed with HIV at the tertiary hospital may
have had more advanced immunosuppression, which
mean that CD4 eligibility thresholds would be met
earlier.
Women had longer delay to ART initiation than men,
possibly reflecting their propensity to be diagnosed earl-
ier in the course of their infection through routine HTC
during antenatal care [8,18]. Men are known to initiate
ART at a more advanced stage of illness and with lower
CD4 counts than women [19] and have a higher risk of
immediate post-ART initiation mortality [20,21]. In this
study, we were not able to adjust for the effect of preg-
nancy (which is associated with diagnosis at an earlier
stage of HIV infection [8]) at ART initiation to deter-
mine whether this could have explained women’s longer
delay. Nevertheless, given that more women currently
access ART in sub-Saharan Africa [2], further studies,
including qualitative research, are required to under-
stand the gendered factors contributing to delay between
HIV diagnosis and initiation of ART.
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initiation of ART can include the complexity and time-
consuming nature of eligibility assessments (CD4 count
measurement and WHO clinical staging) [8,14,22], espe-
cially when these require substantial patient expenditure
and repeat facility visits [23]. Moves towards introducing
point-of-care CD4 count measurement [24] within HIV
testing sites should allow same-day, same-clinic eligibility
assessments reducing delays for men and women, while
the universal ART eligibility of pregnant women infected
with HIV in Malawi (“Option B+”) [25] should result in
more rapid initiation of treatment for pregnant women.
We noted peaks in ART initiations in 2004 and 2005, after
ART became freely available at the clinic through the
national treatment programmes. There are two possible
related reasons for this. Firstly, the large number of in-
dividuals who were awaiting treatment could have
overwhelmed clinic capacity. However, we found that
the number of clients initiating ART per year was not
significantly associated with delay. Alternatively with
treatment guidelines stipulating that only individuals
with advanced immunosuppression (CD4 count <200 cells/
μl were eligible for ART during this time, overall HIV diag-
nosed individuals may have had to wait longer before they
met ART eligibility criteria.
The majority of ART initiators in this study were ado-
lescents and young adults. Adolescents were significantly
more likely to initiate ART with advanced HIV infection
than individuals in other age groups. This supports data
from Zimbabwe showing that HIV-infected adolescents
are a neglected group, with high rates of undiagnosed
HIV [26], late presentation for care with high a preva-
lence of chronic complications [27,28] and numerous
socio-economic complications, including an extremely
high rate of orphanhood of 73% [28] and emotional and
psychological difficulties. We were reassured to find that,
on adjusted analysis, adolescents and young adults did
not have a higher risk of ART treatment delay, and this
may be due to the availability of teen groups and inte-
grated family clinics at QECH supporting access to care.
However, the advanced stage of HIV at which the major-
ity of children and adolescents are diagnosed requires
urgent intervention, perhaps by including HIV screening
as part of regular infant health screening clinics.
There were limitations to this study. We only examined
delay from most recent positive HIV test to initiation of
ART and some individuals may have tested positive on a
prior occasion. Nearly 40% of ART initiators did not have
complete data recorded for either date of most recent
HIV-positive test or ART initiation, meaning that treat-
ment delay may have been under- or over-estimated. As
this was a retrospective cohort study (although using pro-
spectively collected data), we were unable to assess several
unrecorded variables which may have potentially impactedupon delay. Finally, we did not give a time-delineated def-
inition of “delay” and instead used a continuous dependent
variable within our regression models. This avoids over-
simplification of a complex construct and recognises that
criteria for ART initiation have evolved over time. How-
ever, it means that we cannot give a definite proportion of
patients who were “delayed”. New Malawian National
guidelines [11] introduced in September 2011 recommend
that ART is initiated within seven days of confirmed infec-
tion (for those meeting eligibility criteria). Even in the year
with the shortest mean delay to treatment initiation
(2011), only 18% of ART initiators initiated treatment
within 7 days of their most recent positive HIV test. It will
be important to continue to measure ART delays with
regards to this target.
Conclusion
In conclusion, this study reports on substantial improve-
ments in ART treatment delay in the largest facility
providing care in Malawi, despite rapid programmatic
scale-up over eight years. Although these achievements
are impressive in the context of an extremely resource-
limited setting, a considerable decrease in treatment
delay is still required, especially where “test-and-treat”
approaches to ART are being considered. The increased
risk of ART treatment delay among women emphasises
the need to ensure equity in access to care.
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